MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

Search

Ionis Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

72.88 0.66

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

72

Максимум

74.29

Ключови измерители

By Trading Economics

Приходи

270M

124M

Продажби

320M

452M

Марж на печалбата

27.331

Служители

1,069

EBITDA

294M

150M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+6.02% upside

Дивиденти

By Dow Jones

Следващи печалби

29.10.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

4.7B

11B

Предишно отваряне

72.22

Предишно затваряне

72.88

Настроения в новините

By Acuity

67%

33%

346 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

Ionis Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.10.2025 г., 21:10 ч. UTC

Значими двигатели на пазара

Kezar Life Sciences Shares Surge After Break with FDA, Restructuring Plan

16.10.2025 г., 19:03 ч. UTC

Придобивния, сливания и поглъщания

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- 2nd Update

16.10.2025 г., 17:58 ч. UTC

Придобивния, сливания и поглъщания

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- Update

16.10.2025 г., 17:12 ч. UTC

Печалби

Ray-Ban Maker EssilorLuxottica's Revenue Surges to Quarterly Record -- Update

16.10.2025 г., 17:12 ч. UTC

Придобивния, сливания и поглъщания

Canada Signals Limited Concern Over US Government Stakes in Canadian Miners

16.10.2025 г., 16:59 ч. UTC

Придобивния, сливания и поглъщания

Airbus's Takeover of Spirit AeroSystems Plants Gets French Antitrust Clearance

16.10.2025 г., 23:44 ч. UTC

Пазарно говорене

Gold Climbs Amid Safe-Haven Demand -- Market Talk

16.10.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Fall, Tracking Wall Street's Declines -- Market Talk

16.10.2025 г., 23:42 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

16.10.2025 г., 22:15 ч. UTC

Печалби

China Tower: Results Supported by Higher Contributions From Energy, Smart Tower Business >0788.HK

16.10.2025 г., 22:15 ч. UTC

Печалби

China Tower 9-Mos Rev CNY74.32B Vs. CNY72.45B >0788.HK

16.10.2025 г., 22:15 ч. UTC

Печалби

China Tower 9-Mos Net CNY8.71B Vs. Net CNY8.15B >0788.HK

16.10.2025 г., 22:02 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

16.10.2025 г., 22:02 ч. UTC

Пазарно говорене

Santos Drifts Into 'Oversold Territory' -- Market Talk

16.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

16.10.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Health Care Roundup: Market Talk

16.10.2025 г., 20:23 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

16.10.2025 г., 20:23 ч. UTC

Пазарно говорене

Recession Risks to Push Canada Toward October Rate Cut -- Market Talk

16.10.2025 г., 20:20 ч. UTC

Печалби

These Stocks Moved the Most Today: TSMC, Salesforce, HPE, F5, United Airlines, Travelers, J.B. Hunt, Praxis Precision, and More -- Barrons.com

16.10.2025 г., 20:08 ч. UTC

Придобивния, сливания и поглъщания

Jack in the Box to Sell Del Taco With Big Markdown. The Stock Plunged. -- Barrons.com

16.10.2025 г., 19:37 ч. UTC

Придобивния, сливания и поглъщания

Crypto Industry Dives Deeper Into Prediction Markets as Kraken Buys Exchange -- Barrons.com

16.10.2025 г., 19:26 ч. UTC

Печалби

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16.10.2025 г., 19:24 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls on Mild Weather, Ample Storage -- Market Talk

16.10.2025 г., 19:23 ч. UTC

Пазарно говорене

Oil Falls As Oversupply Concerns Outweigh India News -- Market Talk

16.10.2025 г., 19:23 ч. UTC

Печалби

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16.10.2025 г., 18:35 ч. UTC

Пазарно говорене
Печалби

Charles Schwab Logs Another Quarter of Record Revenues, Earnings -- Market Talk

16.10.2025 г., 18:31 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

16.10.2025 г., 18:31 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

16.10.2025 г., 18:31 ч. UTC

Пазарно говорене

Charles Schwab Readies Spot Crypto Trading -- Market Talk

16.10.2025 г., 16:57 ч. UTC

Пазарно говорене

Oil Futures Lose Ground as EIA Reports Crude Stock Build -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ionis Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

6.02% нагоре

12-месечна прогноза

Среден 76.75 USD  6.02%

Висок 96 USD

Нисък 46 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Ionis Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

21 ratings

17

Купи

4

Задържане

0

Продай

Техническа оценка

By Trading Central

29.78 / 33.645Подкрепа & съпротива

Краткосрочен план

Neutral Evidence

Средносрочен план

Very Strong Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

346 / 371 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat